Veracyte’s WGS-based MRD testing platform demonstrated earlier cancer detection in muscle-invasive bladder cancer (MIBC) patients.
Read More
Researchers developed a urine-based diagnostic kit for bladder cancer, offering a solution for early detection and monitoring at home.
Read More
The Oncuria Bladder Cancer Tests, a DiaCarta validated lab developed test (LDT), received Medicare coverage effective Jan. 1, 2024.
Read More
FDA has granted Breakthrough Device Designation to EarlyTect BCD as a non-invasive, urine-based diagnostic for bladder cancer in patients with hematuria.
Read More
This genomic urine test uses next-generation DNA sequencing and machine learning to analyze urine for mutations across 60 genes linked to bladder cancer while also measuring the entire genome.
Read More